Announcements Trials
Browse Landscape

Phase

Phase 2 121Phase 3 29Phase 1 16Phase 1/2 10Phase 4 5Phase NA 4Phase EARLY_PHASE1 4

Status

Completed 3Withdrawn 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Glioblastoma 5Breast Neoplasms 4Brain Neoplasms 3von Hippel-Lindau Disease 1Tonsillar Neoplasms 1Solid Tumor 1Sarcoma 1Prostatic Neoplasms 1Pharyngeal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Optic Nerve Diseases 1Neoplastic Cells, Circulating 1Hemangioblastoma 1Head and Neck Neoplasms 1Gliosarcoma 1Glioma 1Esophageal Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Primary Liver Cancer 1

Interventions

Letrozole 7Fluorodeoxyglucose F18 7Magnetic Resonance Spectroscopy 5Blood Specimen Collection 5pembrolizumab 4atezolizumab 4Trastuzumab 4Oncolytic Virotherapy 4Bevacizumab 4palbociclib 3Saline Solution 3Fish Oils 3Docosahexaenoic Acids 3Denosumab 3Carboplatin 3Biopsy 3pertuzumab 2olaparib 2Vitamin D 2Vinorelbine 2Taxes 2Sentinel Lymph Node Biopsy 2Radiotherapy 2Positron-Emission Tomography 2Positron Emission Tomography Computed Tomography 2Paclitaxel 2Omacor 2Neoadjuvant Therapy 2Metformin 2Lapatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Breast Neoplasms × Bevacizumab × Clear all
NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT00949247 2020-07-27

Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
20 enrolled
Breast

Breast Neoplasms

NCT02802098 2020-06-19

Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer

Centro Nacional de Investigaciones Oncologicas CARLOS III

Phase EARLY_PHASE1 Completed
25 enrolled
Breast

Breast Neoplasms

NCT02806817 2019-07-23

ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism

Centro Nacional de Investigaciones Oncologicas CARLOS III

Phase EARLY_PHASE1 Completed
40 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡